Drug Profile


Alternative Names: Cerovive; CPI 22; Disufenton sodium; NXY 059; NXY 059G

Latest Information Update: 01 Nov 2006

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Renovis
  • Class Anti-ischaemics; Benzenesulfonates; Neuroprotectants; Nitrogen oxides; Small molecules
  • Mechanism of Action Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Stroke

Most Recent Events

  • 01 Nov 2006 Results from the phase III clinical trial SAINT II in patients with acute ischaemic stroke have been added to the adverse events and Neurological disorders therapeutic trials sections ,
  • 26 Oct 2006 Discontinued - Phase-III for Stroke in Asia, Australia, Canada, Europe, New Zealand, South Africa, South America, Sweden, United Kingdom, USA and Japan (IV-infusion)
  • 02 Aug 2006 Renovis has completed enrolment in the SAINT II trial for acute ischaemic stroke
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top